Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT: Pimivalimab alone and with Vopratelimab in metastatic NSCLC
NCT04549025Phase 2Terminated
- Sponsor
- Jounce Therapeutics
- Start
- Oct 2020
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of pimivalimab and vopratelimab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Jounce Therapeutics. Primary endpoint: Change in measurable lesion size at 18 weeks. Started Oct 2020; status: terminated.
02
Drugs
pimivalimabvopratelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04549025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04549025.